<DOC>
	<DOCNO>NCT01485406</DOCNO>
	<brief_summary>The purpose study assess safety , reactogenicity immunogenicity GSK Biologicals ' pneumococcal vaccine 2830930A toddler age 12 23 month study entry .</brief_summary>
	<brief_title>Safety Immunogenicity Study GlaxoSmithKline ( GSK ) Biologicals ' Pneumococcal Vaccine 2830930A Administered Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LARs ) comply requirement protocol . A male female , include 12 23 month age time vaccination . Written inform consent obtain parents/LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Born gestation period least 36 week . Previously complete threedose vaccination course Synflorix . Child care . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/administration vaccine contain diphtheria tetanus toxoid CRM197 foreseen study protocol time study period , vaccine foresee protocol period start 30 day vaccine dose end 30 day , exception license influenza vaccine . The licensed influenza vaccine always allow , even concomitantly administer study vaccine document `` Concomitant vaccination '' electronic Case Report Form . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness , include Kawasaki 's syndrome . History neurological disorder seizure , include condition hypotensivehyporesponsive episode , encephalopathy convulsion ( afebrile febrile ) . Acute disease and/or fever time enrolment . Administration immunoglobulins and/or blood product within 3 month precede vaccination plan administration study period . Any medical condition might interfere assessment study objective opinion investigator . Previous receipt booster dose ( fourth dose ) Synflorix . Anaphylaxis follow previous administration vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Haemophilus influenzae</keyword>
	<keyword>Safety</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Toddlers</keyword>
</DOC>